Vistagen Therapeutics (VTGN) EBT Margin (2011 - 2026)
Vistagen Therapeutics' (VTGN) quarterly EBT Margin came in at 882.79% in Q2 2026, up 530368.0% year-over-year from N/an in Q2 2025, and up 74.8% quarter-over-quarter from 3503.01% in Q1 2026.
Powered by 
Analysis
Vistagen Therapeutics (VTGN) EBT Margin (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has disclosed EBT Margin across 10 years of filings, most recently posting 882.79% for Q2 2026.
- In Q2 2026, EBT Margin rose 530368.0% year-over-year to 882.79%; the TTM figure through Jun 2026 stood at 2703.24% (up 593035.0% YoY), while the FY2026 annual figure was 5492.51%, up 508588.0% from the prior year.
- EBT Margin came in at 882.79% for Q2 2026 at Vistagen Therapeutics, up from 3503.01% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 90900.0% in Q1 2025 to a low of 42789.74% in Q1 2022.
- Average EBT Margin over 5 years is 1988.95%, with a median of 5912.91% recorded in 2024.
- Year-over-year, EBT Margin jumped 9670488 bps in 2025 and sank 9440301 bps in 2026.
- Over 5 years, EBT Margin stood at 5422.89% in 2022, then soared by 72 bps to 1545.01% in 2023, then plunged by 290 bps to 6020.94% in 2024, then dropped by 4 bps to 6237.29% in 2025, then soared by 86 bps to 882.79% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 882.79% in Q2 2026, 3503.01% in Q1 2026, and 6237.29% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.71 Bn | 192.72 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.26 Bn | 177.08 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.29 Bn | 123.43 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.82 Bn | 73.83 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.94 Bn | 48.80 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.34 Bn | 30.03 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.87 Bn | 30.58 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | -20,427.46% |
| 10 | Vistagen Therapeutics | 10.23 Mn | 10.23 Mn | - | -882.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -882.79% |
| Mar 31, 2026 | -3,503.01% |
| Dec 31, 2025 | -6,237.29% |
| Sep 30, 2025 | -7,525.97% |
| Jun 30, 2025 | -6,186.48% |
| Mar 31, 2025 | 90,900.00% |
| Dec 31, 2024 | -6,020.94% |
| Sep 30, 2024 | -7,078.69% |
| Jun 30, 2024 | -12,777.38% |
| Mar 31, 2024 | -5,804.88% |
| Dec 31, 2023 | -1,545.01% |
| Sep 30, 2023 | -2,196.00% |
| Jun 30, 2023 | -3,450.00% |
| Mar 31, 2023 | -6,946.59% |
| Dec 31, 2022 | -5,422.89% |
| Sep 30, 2022 | -1,957.81% |
| Jun 30, 2022 | -6,375.62% |
| Mar 31, 2022 | -42,789.74% |
| Dec 31, 2021 | -2,942.46% |
| Sep 30, 2021 | -3,574.02% |